Skip to main content

Table 1 AAS-Lynch eligibility criteria

From: Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial

Inclusion criteria

Exclusion criteria

 - Men and women with Lynch syndrome with an alteration of “mismatch repair” genes or when no characteristic alteration has been found, with a personal or family history of Lynch syndrome according to modified Amsterdam criteria.

 - Aged over 25 or 18 years of age in cases with an early family history, with an indication for colonoscopic surveillance every 2 years

 - Under 75 years old.

 - Performing a colonoscopy within 180 days before inclusion, with removal of all endoscopically resectable polyps.

 - No regularly use of aspirin throughout the (7 consecutive days for at least 3 weeks per year or more than 21 days throughout the year).

 - Effective contraception for women of, defined by a hormonal method or IUD or surgical sterilization of the patient or her partner

 - Patient affiliated to a social security (excluding AME) or entitled

 - Patient who has given his consent to participate by signing the consent of the study

- Total colectomy

- Adenomatous polyposis associated with known alteration of APC gene or MYH gene

- Allergy to aspirin (including a history of asthma induced by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs)

- Allergy known to indigo carmine used for chromoendoscopy

- Indication of prolonged treatment (prevention of atheromatous risk) or repeated treatment (recurrent migraine) with aspirin or other nonsteroidal anti-inflammatory drug (NSAID)

- Abnormality of hemostasis or coagulation (including gastrointestinal hemorrhage, history of hemorrhagic stroke and thrombocytopenia)

- Indication of long-term treatment with anticoagulant antiplatelet agents, anagrelide or uricosuric agents- History of digestive ulcer

- Digestive hemorrhage related to ulcerative disease in the 12 months prior to inclusion

- Gastric pathology deemed significant by the investigator and not corrected by appropriate treatment

- Uncontrolled high blood pressure

- Renal insufficiency (creatinine clearance < 30 ml/min)

- Severe hepatic insufficiency (defined by a PT < 70%)

- Severe uncontrolled heart failure

- Known failure of G6PD deficit

- Recent diagnosis of colorectal cancer requiring specific management

- Presence of menorrhagia and not corrected by appropriate treatment

- Pregnancy or breastfeeding

- Any disease that may interfere with the follow-up provided by the protocol or invalidate the proper understanding of the protocol information and informed consent

- Patient under the protection of justice

- Participation in another therapeutic clinical trial in the 12 weeks prior to inclusion